Company intelligence / Profile preview
IM Biologics
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
IM Biologics is a clinical-stage South Korean biotechnology company specializing in the development of innovative antibody therapeutics for autoimmune and inflammatory diseases. Founded by experts from HK inno.N, the company leverages its proprietary ePENDY platform to create multispecific antibodies with enhanced efficacy and safety profiles. Its lead candidate, IMB-101, is a first-in-class bispecific antibody targeting both OX40L and TNF, currently undergoing clinical evaluation for rheumatoid arthritis. The company has successfully secured significant licensing deals, including a major global partnership with Navigator Medicines, highlighting the high potential of its immunology pipeline.
- Therapeutic areas
- ImmunologyDermatologyGastroenterology
- Modalities
- AntibodyBispecific monoclonal antibodyMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Navigator MedicinesHK inno.NY-Biologics
Beyond the preview
Go deeper on IM Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM Biologics.